| References |
Top |
| REF 1 |
Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood. 1997 May 1;89(9):3166-74.
|
| REF 2 |
Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras pathway. J Biol Chem. 1996 May 24;271(21):12129-32.
|
| REF 3 |
Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis. Blood. 1996 Jun 1;87(11):4495-501.
|
| REF 4 |
Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J Biol Chem. 1995 Mar 10;270(10):5631-5.
|
| REF 5 |
Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activity. J Biol Chem. 1997 May 30;272(22):14334-40.
|
| REF 6 |
Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity. J Biol Chem. 1995 Oct 6;270(40):23402-8.
|
| REF 7 |
A systematic scan of interactions with tyrosine motifs in the erythropoietin receptor using a mammalian 2-hybrid approach. Blood. 2005 Jun 1;105(11):4264-71.
|
| REF 8 |
Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors. Blood. 2004 Jun 15;103(12):4457-65.
|
| REF 9 |
The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001 Dec;8(6):1327-38.
|
| REF 10 |
Physical and functional interactions between Stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3. Blood. 1996 Dec 15;88(12):4415-25.
|
| REF 11 |
APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl. Leukemia. 1999 May;13(5):760-7.
|
| REF 12 |
Design and application of a cytokine-receptor-based interaction trap. Nat Cell Biol. 2001 Dec;3(12):1114-9.
|
| REF 13 |
The C-terminus of CIS defines its interaction pattern. Biochem J. 2007 Jan 1;401(1):257-67.
|
| REF 14 |
Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509.
|
| REF 15 |
beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood. 2007 Jun 15;109(12):5215-22.
|
| REF 16 |
Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide. J Biol Chem. 1999 May 14;274(20):14163-9.
|
| REF 17 |
Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood. 2005 Jan 15;105(2):600-8.
|
| REF 18 |
Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR. Cell Signal. 2017 Feb;31:41-57.
|
| REF 19 |
CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem. 2000 Sep 22;275(38):29338-47.
|
| REF 20 |
A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur J Biochem. 2002 May;269(10):2516-26.
|
